-
Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipientsGrego, Katarina ...In this prospective, randomized, open-label, single-center study, we compared the efficacy and safety of two anti-interleukin-2 receptor monoclonal antibodies among adult recipients of at least 1 ... HLA-mismatched deceased donor renal grafts. Eligible patients were randomized to induction with either basiliximab or daclizumab. Both groups received cyclosporine microemulsion (CsA Neoral), mycophenolate mofetil, and methylprednisolone. An intent-to-treat analysis of 1-year data assessed the incidence of acute rejection episodes, the renal graft function, the safety, and the patient and graft survivals. Among 127 patients, six (10.0%) and seven (11.5%) patients experienced biopsy-confirmed acute rejection at 12 months, in the basiliximab and the daclizumab groups, respectively. Two renal grafts were lost in the basiliximab and six in the daclizumab cohort, one of them due to rejection. One basiliximab and two daclizumab patients died. Hospital treatment was required for 25 and 33 infections in basiliximab and daclizumab groups, respectively. One basal cell carcinoma of skin was detected. One hypersensitivity reaction was observed with daclizumab. At 12 months, serum creatinine was 101+/-28 micromol/L with basiliximab and 109+/-41 micromol/L with daclizumab. Patient survival was 98.4% with basiliximab and 96.7% with daclizumab, and graft survival was 96.8% versus 90.8%, respectively. No significant differences were observed between the groups. Basiliximab or daclizumab combined with triple therapy was an efficient and safe immunosuppression strategy, demonstrated with low incidence of acute rejectionepisodes, an acceptable adverse event profile, excellent graft function, and high survival rates in adult recipients within the first year after deceased donor renal transplantation.Vir: Transplantation Proceedings. - ISSN 0041-1345 (Letn. 39, št. 10, 2007, str. 3093-3097)Vrsta gradiva - članek, sestavni delLeto - 2007Jezik - angleškiCOBISS.SI-ID - 24207065
Avtor
Grego, Katarina |
Arnol, Miha |
Bren, Andrej |
Kmetec, Andrej |
Tomažič, Janez, 1954- |
Kandus, Aljoša
Teme
Adult |
Aged |
Antibodies, Monoclonal |
Therapeutic Use |
Cyclosporine |
Blood |
Therapeutic Use |
Drug Therapy, Combination |
Histocompatibility Testing |
Hospitalization |
Statistics & Numerical Data |
Immunosuppressive Agents |
Therapeutic Use |
Kidney Transplantation |
Immunology |
Postoperative Complications |
Classification |
Recombinant Fusion Proteins |
Therapeutic Use |
Safety |
Tissue Donors |
Statistics & Numerical Data |
Treatment Outcome |
Protitelesa monoklonska |
Ciklosporin |
Rekombinantne, fuzijske beljakovine |
Starostniki |
Odrasli |
Histokompatibilnost, testiranje |
Pooperativne komplikacije |
Tkivodajalci |
Imunosupresivi |
Ledvica, presaditev |
Zdravljenje, izid |
Varnost |
Zdravilo, terapija sestavljena |
Hospitalizacija
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Grego, Katarina | 24468 |
Arnol, Miha | 21624 |
Bren, Andrej | 01972 |
Kmetec, Andrej | 14914 |
Tomažič, Janez, 1954- | 11347 |
Kandus, Aljoša | 01977 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.